COMMUNIQUÉS West-GlobeNewswire

GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 30 avril 2024

21/05/2024 - 12:07

GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 30 avril 2024 En application de l'article L. 233-8 II du code de commerce et de l'article 222-12-5 du règlement général de l'AMF, les [...]

Engitix Announces Appointment of Matthew Edwards Ph.D., as SVP Discovery and Emma Huang Ph.D., as VP Data Sciences

21/05/2024 - 10:25

LONDON, May 21, 2024 (GLOBE NEWSWIRE) -- Engitix Ltd (‘Engitix’), a biotechnology company with a portfolio of drug discovery programmes in fibrosis and solid tumours using its proprietary human extracellular matrix (ECM [...]

Medigene's Global Research & Collaboration Agreement with BioNTech to Extend Beyond Initially Announced Term

21/05/2024 - 10:00

Planegg/Martinsried, May 21, 2024 . Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of differentiated T cell [...]

CancerVax Successfully Uses Nobel Prize Chemistry to Achieve Universal Cancer Vaccine Targeting Milestone

21/05/2024 - 09:00

The UCLA research team created a low cost and customizable lipid nanoparticle using “click chemistry” for precise targeting of cancer cell surface markers Santa Barbara, May 21, 2024 (GLOBE NEWSWIRE) -- Santa Barbara, [...]

Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration

21/05/2024 - 07:30

Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration Paris, New York, N.Y., and San Francisco, CA, May 21, 2024 . Sanofi, Formation Bio and OpenAI are collaborating to build AI-powered software to [...]

Communiqué de presse : Sanofi, Formation Bio et OpenAI annoncent une coopération de première classe autour de l’IA

21/05/2024 - 07:30

Sanofi, Formation Bio et OpenAI annoncent une coopération de première classe autour de l’IA Paris, New York, New York et San Francisco, Californie, 21 mai 2024. Sanofi, Formation Bio et OpenAI collaborent afin de [...]

Valneva Appoints Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer

21/05/2024 - 07:00

Saint-Herblain (France), May 21, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced the appointment of Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer (CSO) [...]

Valneva annonce la nomination du Dr Hanneke Schuitemaker en tant que Directeur Scientifique

21/05/2024 - 07:00

Saint-Herblain (France), le 21 mai 2024 – Valneva SE (Nasdaq : VALN; Euronext Paris : VLA), société spécialisée dans les vaccins, a annoncé aujourd’hui la nomination du Dr Hanneke Schuitemaker, Ph.D. en tant que [...]

FDA grants Breakthrough Therapy Designation to Roche’s inavolisib for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation

21/05/2024 - 07:00

The designation is based on Phase III INAVO120 results, showing the inavolisib-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the first-line setting 1 [...]

Idorsia announces changes to Idorsia Executive Committee and Board of Directors

21/05/2024 - 07:00

Ad hoc announcement pursuant to Art. 53 LR Jean-Paul Clozel to retire as CEO and stand for election as Chairman of the Board of Directors Mathieu Simon to stand for re-election to the Board – taking on the role of Vice- [...]

Idorsia announces financial results for the first quarter 2024 – advancing the company with renewed vigor

21/05/2024 - 06:50

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – May 21, 2024 Idorsia Ltd (SIX: IDIA) today announced its financial results for the first quarter of 2024. Business highlights Viatris collaboration : [...]

Idorsia announces financial results for the full year of 2023 – Adapting the company to create sustainable value

21/05/2024 - 06:40

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – May 21, 2024 Idorsia Ltd (SIX: IDIA) today announced its financial results for the full year of 2023. Business highlights Sale of Idorsia Asia-Pacific [...]

Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.

21/05/2024 - 02:25

SIMLANDI is the first interchangeable high-concentration, citrate-free biosimilar to Humira ® REYKJAVIK, Iceland and PARSIPPANY, N.J., May 21, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva [...]

Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.

21/05/2024 - 02:25

SIMLANDI is the first interchangeable high-concentration, citrate-free biosimilar to Humira® REYKJAVIK, ICELAND & PARSIPPANY, NJ — Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE [...]

Telix Completes Proof-of-Concept Study of TLX592 Targeted Alpha Therapy in Prostate Cancer

21/05/2024 - 01:46

CUPID is a Phase I safety and dosimetry study of TLX592, Telix’s investigational antibody-based targeted alpha therapy for prostate cancer. Establishes proof-of-concept for Telix’s proprietary RADmAb® engineered [...]

NADP Advocates for Improved Access to Dental Benefits and Care

21/05/2024 - 00:00

Congress Urged to Support Technical Fix to Healthcare.gov DALLAS, May 20, 2024 (GLOBE NEWSWIRE) -- Improving access to dental benefits and care was the main objective of Advocacy in Action, the National Association of [...]

SAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company Updates

20/05/2024 - 23:45

MIAMI, May 20, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti- [...]

Cytek® Biosciences Adds Ability to Detect Subcellular Particles to Its Industry-Leading Cell Analysis Systems

20/05/2024 - 23:30

New Enhanced Small Particle (ESP™) Detection Option for Cytek Northern Lights™ and Cytek Aurora™ Systems Expands Capabilities of Small Particle Research FREMONT, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- Today Cytek [...]

Aerami Therapeutics Presents New Lung Deposition Modeling Data For AER-901 in Pulmonary Hypertension at the American Thoracic Society 2024 International Conference

20/05/2024 - 23:00

DURHAM, N.C., May 20, 2024 (GLOBE NEWSWIRE) -- Aerami Therapeutics (“Aerami”) , a clinical stage biopharmaceutical company dedicated to breathing life into the treatment of serious and rare cardiopulmonary diseases, [...]